Table 4 Pralsetinib safety overview
From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer
TRAEs with Pralsetinib (BLU-667), % | ARROW safety population* (N = 354) | |
|---|---|---|
Any | Grade ≥ 3 | |
AST | 31 | 2 |
Anemia | 22 | 8 |
ALT increased | 21 | 1 |
Constipation | 21 | 1 |
Hypertension | 20 | 10 |
Neutropenia | 19 | 10 |
Diarrhea | 14 | 1 |
WBC decreased | 14 | 3 |
Dysgeusia | 13 | 0 |
Creatinine increased | 13 | 0 |
Neutrophil Count Decreased | 13 | 4 |